NVCR — Novocure Ltd

Summary of NovoCure's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $174 million, up 12% year-over-year, driven by growth in international markets, particularly Germany and France.
• Optune Lua Revenue: Increased to $3 million from $1.5 million in Q1 2025.
• Gross Margin: Improved to 78% from 75% in Q1 2025, attributed to lower array costs.
• Net Loss: $71 million, compared to $34 million in Q1 2025. Excluding a one-time share-based compensation charge, the adjusted net loss was $28 million.
• Adjusted EBITDA: Negative $0.3 million, an improvement from negative $5 million in Q1 2025.
• Cash and Investments: $432 million as of March 31, 2026.
• Updated Revenue Guidance: Full-year revenue guidance raised to $690 million - $710 million (5% to 8% growth).

2. Strategic Updates and Business Highlights

• Optune Pax Launch: FDA approved on February 11, 2026, with positive early feedback. 868 healthcare providers certified, with 169 prescriptions and 90 patient starts within the first 7 weeks. Notable payer coverage from Elevance Health.
• Pancreatic Cancer Program: Strong early results from the PANOVA-4 trial, showing a disease control rate of 74%. The company is exploring synergies with RAS inhibitors.
• Product Enhancements: Improvements in patient experience and usability for TTFields therapy, including a new array for the torso expected by year-end.
• GBM and Lung Cancer Programs: Continued growth in Optune Gio with a 9% increase in active patients. Upcoming data from the Phase III TRIDENT trial expected in Q2.

3. Forward Guidance and Outlook

• Revenue Growth: Anticipated to maintain low to mid-single-digit growth in mature markets, with potential for double-digit growth driven by new indications like pancreatic cancer.
• Adjusted EBITDA Guidance: Updated to a range from negative $15 million to breakeven for the year, reflecting strong early performance.
• Long-term Growth Strategy: Focus on achieving double-digit revenue growth and profitability, leveraging the success of Optune Pax and expanding in new markets.

4. Bad News, Challenges, or Points of Concern

• Net Loss Increase: The net loss widened significantly due to a large share-based compensation charge.
• High G&A Costs: General and administrative expenses surged by 92% year-over-year, primarily due to the aforementioned share-based compensation.
• Reimbursement Dynamics: Uncertainty remains regarding the adoption curve and reimbursement for Optune Pax, with a lengthy process expected for broader payer coverage.
• Competitive Landscape: The emergence of new therapies, such as RAS inhibitors, could impact market dynamics, although management believes Optune Pax has a unique positioning.

5. Notable Q&A Insights

• Optune Pax Launch: Early metrics indicate a strong response from both community and academic centers, with significant pent-up demand noted.
• Conversion Rates: The company is optimistic about converting prescriptions to active patients, with a typical conversion time of about two weeks.
• Market Potential: Management believes that the pancreatic cancer indication could ultimately surpass GBM in terms of patient population and revenue potential.
• Regulatory Engagement: Ongoing discussions with payers and regulators regarding coverage and reimbursement strategies for Optune Pax.

Overall, NovoCure's first quarter of 2026 demonstrated strong revenue growth and promising developments in its product pipeline, particularly with the launch of Optune Pax for pancreatic cancer. However, challenges remain, particularly regarding net losses and reimbursement dynamics.